AccessibilityHelpAbout Us
EMVision Medical Devices logo

EMVision Medical Devices(ASX) EMV

Market CapA$162.21MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)+472%
5 Year-39%
1 Year-24%
1 Month-1%
A$1.75
+0.00%
+0.00Today
EMVision Medical Devices last closing stock price
MetricPriceDate
Last closeAUD 1.752026-09-11
EMVision Medical Devices stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.18%AUD 1.882026-09-04
1 month-1.13%AUD 1.772026-08-12
3 month+11.15%AUD 1.572026-06-12
Year to date-1.97%AUD 1.782025-12-31
1 year-23.8%AUD 2.292025-09-11
3 year+6.4%AUD 1.642023-09-12
5 year-38.77%AUD 2.852021-09-10
Since inception+472.13%AUD 0.312018-12-13

EMVision Medical Devices Financials at a Glance

Market Cap

A$162.21MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$5.05M

Net Income (TTM)

-A$18.12M

EPS (TTM)

-A$0.09

P/E Ratio

-19.11

Dividend

A$0.00

Beta (Volatility)

-0.10 (Low)

Price

A$1.75

Volume

5,920

Open

A$1.75

Previous Close

A$1.75

Daily Range

A$1.70 - A$1.75

52-Week Range

A$1.47 - A$2.36

Estimated Earnings Date

Feb 24, 2027

EMV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About EMVision Medical Devices

EMVision Medical Devices Ltd is an innovative Australian company focused on developing advanced imaging and diagnostic healthcare technologies. The company specializes in a compact, mobile brain scanner designed for rapid stroke detection and continuous monitoring, addressing critical medical imaging needs.

Products and Services
  • Compact mobile brain scanner for stroke detection
  • Advanced imaging technologies for various medical applications
  • Continuous tracking solutions for patient diagnostics
Growth Outlook
  • Strong demand for portable medical imaging solutions is increasing
  • Partnerships with healthcare providers enhance market reach
  • Focus on R&D aims to expand product offerings and capabilities
Financial Highlights
  • Recent quarterly revenue of AUD 0 indicates ongoing development phase
  • Cash and cash equivalents of AUD 17.1 million support operational needs
  • Current ratio of 5.53 suggests strong liquidity position
EMVision Medical Devices Ltd is positioned in the healthcare sector, specifically within medical devices, and has been operational since 2017. The company is headquartered in Macquarie Park, Australia, and employs a dedicated team of 46 professionals. The innovative mobile brain scanner is a key product, aimed at improving patient outcomes through timely stroke detection. The growth outlook for EMVision is promising, driven by increasing demand for portable imaging solutions and strategic partnerships that enhance market penetration. The focus on research and development is expected to lead to expanded product offerings, further solidifying the company's position in the healthcare market. Financially, EMVision is in a development phase, with recent quarterly reports showing no revenue as the company continues to invest in its technology and market introduction. However, a robust cash position of AUD 17.1 million provides a solid foundation for ongoing operations and development. The current ratio of 5.53 indicates a strong liquidity position, allowing the company to meet its short-term obligations effectively. Overall, EMVision Medical Devices Ltd represents an intriguing opportunity in the medical technology space, with its innovative products and strategic growth initiatives.
AI Generated • Sep 4, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Scott Kirkland

Website

www.emvision.com.au

Headquarters

Macquarie Park, NSW 2113, AU

EMV Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-46.84%

Return on Capital

-88.30%

Return on Assets

-36.10%

Earnings Yield

-5.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$162.21MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

92.96M

Volume

5.92K

Avg. Volume

34.40K

Financials (TTM)

Gross Profit

A$4.63M

Operating Income

-A$25.06M

EBITDA

-A$24.95M

Operating Cash Flow

-A$14.08M

Capital Expenditure

-A$174.60K

Free Cash Flow

-A$14.26M

Cash & ST Invst.

A$17.10M

Total Debt

A$3.41M

EMVision Medical Devices Performance Analysis

EMVision Medical Devices annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
EMVision Medical Devices sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-23.7%
Q42025-06-30-55.2%
Q22025-12-31-100.0%
Q42026-06-30N/A
EMVision Medical Devices annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.05-38.7%
20242024-06-30AUD -0.03-31.9%
20252025-06-30AUD -0.11238.6%
20262026-06-30AUD -0.09-20.5%
EMVision Medical Devices sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-32.3%
Q42025-06-30-74.6%
Q22025-12-3139.0%
Q42026-06-30-5.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$202.18K

-104.4%

Gross Margin

0.00%

N/A

Market Cap

A$162.21MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$3.53M

N/A

Employees

46

N/A

Net Income

-A$4.35M

-66.2%

EBITDA

-A$8.82M

-273.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$17.10M

-8.4%

Total Debt

A$3.41M

+17.4%

Accounts Receivable

A$4.36M

+56.0%

Inventory

A$0.00

+100.0%

Long Term Debt

A$3.14M

+71.2%

Short Term Debt

A$270.71K

-74.7%

Return on Assets

-36.10%

N/A

Return on Invested Capital

-88.56%

N/A

Free Cash Flow

-A$372.56K

+92.1%

Operating Cash Flow

-A$306.44K

+93.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NYR.AXNyrada Inc.
A$0.71-1.39%
ONE.AXOneview Healthcare PLC
A$0.17+0.00%
PAR.AXParadigm Biopharmaceuticals Limited
A$0.24-15.79%
ALC.AXAlcidion Group Limited
A$0.11+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
KHCKraft Heinz
$24.60+0.01%
ACVAACV Auctions
$10.41+0.44%
TNONTenon Medical
$5.93+0.12%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.16+0.03%

Questions About EMV

What is the current price of EMVision Medical Devices?

EMVision Medical Devices is trading at A$1.75 per share.

What is the 52-week range for EMVision Medical Devices?

Over the past 52 weeks, EMVision Medical Devices has traded between A$1.47 and A$2.36.

How much debt does EMVision Medical Devices have?

As of the most recent reporting period, EMVision Medical Devices reported total debt of A$3.41M.

How much cash does EMVision Medical Devices have on hand?

EMVision Medical Devices reported A$17.10M in cash and cash equivalents in its most recent financial results.

What is EMVision Medical Devices’s dividend yield?

EMVision Medical Devices does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services